About: Bococizumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."

Property	Value
dbo:abstract	Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders." (en)
dbo:casNumber	1407495-02-6
dbo:chEMBL	3137349
dbo:fdaUniiCode	45M75JVK38
dbo:kegg	D10621
dbo:wikiPageID	44875620 (xsd:integer)
dbo:wikiPageLength	5329 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1124047784 (xsd:integer)
dbo:wikiPageWikiLink	dbc:PCSK9_inhibitors dbr:Pfizer dbc:Experimental_drugs dbr:Monoclonal_antibody dbr:Statin dbr:Subcutaneous_injection dbr:Drug_development dbr:PCSK9 dbr:Cardiovascular_disease dbr:Protein dbc:Hypolipidemic_agents dbr:Cholesterol dbr:LDL dbr:United_States_Adopted_Name dbr:Phases_of_clinical_research dbr:LDL-C
dbp:atcPrefix	none (en)
dbp:c	6414 (xsd:integer)
dbp:casNumber	1407495 (xsd:integer)
dbp:chembl	3137349 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9918 (xsd:integer)
dbp:iupharLigand	7730 (xsd:integer)
dbp:kegg	D10621 (en)
dbp:legalStatus	Investigational (en)
dbp:mabType	mab (en)
dbp:n	1722 (xsd:integer)
dbp:o	2012 (xsd:integer)
dbp:pubchemsubstance	194168554 (xsd:integer)
dbp:routesOfAdministration	dbr:Subcutaneous_injection
dbp:s	54 (xsd:integer)
dbp:source	zu/o (en)
dbp:target	Proprotein convertase subtilisin/kexin type 9 (en)
dbp:type	mab (en)
dbp:unii	45 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Infobox_drug dbt:Reflist dbt:Short_description dbt:Fdacite dbt:Keggcite dbt:Lipid_modifying_agents dbt:Monoclonal-antibody-stub dbt:Cardiovascular-system-drug-stub
dcterms:subject	dbc:PCSK9_inhibitors dbc:Experimental_drugs dbc:Hypolipidemic_agents
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders." (en)
rdfs:label	Bococizumab (en)
owl:sameAs	freebase:Bococizumab yago-res:Bococizumab wikidata:Bococizumab https://global.dbpedia.org/id/soH5
prov:wasDerivedFrom	wikipedia-en:Bococizumab?oldid=1124047784&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Bococizumab
is dbo:wikiPageRedirects of	dbr:C6414H9918N1722O2012S54 dbr:RN316
is dbo:wikiPageWikiLink of	dbr:C6414H9918N1722O2012S54 dbr:PCSK9 dbr:Hypercholesterolemia dbr:List_of_therapeutic_monoclonal_antibodies dbr:RN316
is foaf:primaryTopic of	wikipedia-en:Bococizumab

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License